These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8834840)

  • 1. [Effect of intravenous treatment with tumor necrosis factor alpha in patients with advanced cancer--phase I clinical trials].
    Muc M; Baranowski M
    Przegl Lek; 1995; 52(10):496-8. PubMed ID: 8834840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.
    Whitehead RP; Fleming T; Macdonald JS; Goodman PJ; Neefe J; Braun TJ; Swinnen LJ; Hersh EM
    J Biol Response Mod; 1990 Dec; 9(6):588-91. PubMed ID: 2074444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
    Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
    Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor.
    Steinmetz T; Schaadt M; Gähl R; Schenk V; Diehl V; Pfreundschuh M
    J Biol Response Mod; 1988 Oct; 7(5):417-23. PubMed ID: 3183683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
    Taguchi T
    Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial.
    Lenk H; Tanneberger S; Müller U; Shiga T
    Arch Geschwulstforsch; 1988; 58(2):89-97. PubMed ID: 3377652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
    Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
    Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
    Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
    J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor in advanced gastrointestinal neoplasms. A clinical trial with a focus on haematological effects.
    Muc-Wierzgoń M; Baranowski M; Madej K
    Haematologia (Budap); 1996; 27(2):85-92. PubMed ID: 14651225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma.
    Schaadt M; Pfreundschuh M; Lorscheidt G; Peters KM; Steinmetz T; Diehl V
    J Biol Response Mod; 1990 Apr; 9(2):247-50. PubMed ID: 2341863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
    McLoughlin JM; McCarty TM; Cunningham C; Clark V; Senzer N; Nemunaitis J; Kuhn JA
    Ann Surg Oncol; 2005 Oct; 12(10):825-30. PubMed ID: 16132372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
    Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
    Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient increase of plasma interleukin-6 after infusion of recombinant tumor necrosis factor alpha in advanced cancer patients.
    Zubelewicz B; Romanowski W; Braczkowska B; Lissoni P; Braczkowski R
    J Exp Clin Cancer Res; 1998 Dec; 17(4):449-52. PubMed ID: 10089067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recombinant human tumor necrosis factor alpha (TNF): preclinical studies and results of early clinical trials].
    Płuzańska A
    Acta Haematol Pol; 1994; 25(2 Suppl 1):148-54. PubMed ID: 8067200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
    Zamkoff KW; Newman NB; Rudolph AR; Young J; Poiesz BJ
    J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
    Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
    Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.
    Conkling PR; Chua CC; Nadler P; Greenberg CS; Doty E; Misukonis MA; Haney AF; Bast RC; Weinberg JB
    Cancer Res; 1988 Oct; 48(19):5604-9. PubMed ID: 3046744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical probes using tumor necrosis factor in treatment of neoplastic diseases].
    Szczepanik A; Tabor J; Siedlar M
    Przegl Lek; 1994; 51(11):497-500. PubMed ID: 7871196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.